The Role of Target Binding Kinetics in Drug Discovery.
Traditionally structure-activity/affinity relationships (SAR) have dominated research in medicinal chemistry. However, structure-kinetics relationships (SKR) can be very informative too. In this viewpoint we explore the molecular determinants of binding kinetics and discuss challenges for future binding kinetics studies. A scheme for future kinetics-directed drug design and discovery is also proposed.
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), P.O. Box 9502, 2300 RA, Leiden, the Netherlands.
Dong
D
Guo
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), P.O. Box 9502, 2300 RA, Leiden, the Netherlands.
Laura H
LH
Heitman
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), P.O. Box 9502, 2300 RA, Leiden, the Netherlands. IJzerman@lacdr.leidenuniv.nl.
Adriaan P
AP
IJzerman
D001665:Binding Sites; D055808:Drug Discovery; D007700:Kinetics; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism*; D013329:Structure-Activity Relationship
D004364:Pharmaceutical Preparations
G protein-coupled receptors; binding kinetics; residence time; structure-affinity relationships; structure-kinetics relationships